ATE401893T1 - Thiophenepyrimidinone als 17-beta-hydroxysteroid dehydrogenase inhibitoren - Google Patents
Thiophenepyrimidinone als 17-beta-hydroxysteroid dehydrogenase inhibitorenInfo
- Publication number
- ATE401893T1 ATE401893T1 AT04739738T AT04739738T ATE401893T1 AT E401893 T1 ATE401893 T1 AT E401893T1 AT 04739738 T AT04739738 T AT 04739738T AT 04739738 T AT04739738 T AT 04739738T AT E401893 T1 ATE401893 T1 AT E401893T1
- Authority
- AT
- Austria
- Prior art keywords
- thiophenepyrimidinone
- beta
- hydroxysteroid dehydrogenase
- dehydrogenase inhibitors
- inhibitors
- Prior art date
Links
- 108010070743 3(or 17)-beta-hydroxysteroid dehydrogenase Proteins 0.000 title 1
- 102100034067 Dehydrogenase/reductase SDR family member 11 Human genes 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Gynecology & Obstetrics (AREA)
- Addiction (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47701703P | 2003-06-10 | 2003-06-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE401893T1 true ATE401893T1 (de) | 2008-08-15 |
Family
ID=33551663
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04739738T ATE401893T1 (de) | 2003-06-10 | 2004-06-09 | Thiophenepyrimidinone als 17-beta-hydroxysteroid dehydrogenase inhibitoren |
Country Status (18)
Country | Link |
---|---|
US (3) | US7754709B2 (de) |
EP (1) | EP1635840B1 (de) |
JP (1) | JP4612628B2 (de) |
CN (1) | CN100502876C (de) |
AR (1) | AR044649A1 (de) |
AT (1) | ATE401893T1 (de) |
AU (1) | AU2004246791B2 (de) |
BR (1) | BRPI0411319A (de) |
CA (1) | CA2527591A1 (de) |
DE (1) | DE602004015287D1 (de) |
DK (1) | DK1635840T3 (de) |
ES (1) | ES2311156T3 (de) |
HK (1) | HK1087331A1 (de) |
PL (1) | PL1635840T3 (de) |
PT (1) | PT1635840E (de) |
SA (1) | SA04250158B1 (de) |
TW (1) | TW200504078A (de) |
WO (1) | WO2004110459A1 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7524853B2 (en) | 2003-06-10 | 2009-04-28 | Solvay Pharmaceuticals B.V. | Compounds and their use in therapy |
JP2008517061A (ja) * | 2004-10-20 | 2008-05-22 | コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー | 抗腫瘍剤としての化合物及びそれらの使用 |
MX2007007051A (es) * | 2004-12-13 | 2007-06-26 | Solvay Pharm Gmbh | Nuevos derivados de tiofenpirimidiona sustituida como inhibidores de la 17??-hidroxiesteroide deshidrogenasa. |
GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
EP2013176A2 (de) * | 2006-02-27 | 2009-01-14 | Sterix Limited | Diarylverbindungen als nichtsteroidale inhibitoren von 17-beta-hydroxysteroiddehydrogenase und/oder steroidsulfatase zur behandlung von mit östrogen in zusammenhang stehenden krankheiten wie hormonabhängigem brustkrebs |
US7855225B2 (en) | 2006-03-02 | 2010-12-21 | Astellas Pharma Inc. | 17βHSD type 5 inhibitor |
US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
DE102007015169A1 (de) | 2007-03-27 | 2008-10-02 | Universität des Saarlandes Campus Saarbrücken | 17Beta-Hydroxysteroid-Dehydrogenase-Typ1-Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
DE102007040243A1 (de) | 2007-08-25 | 2009-02-26 | Universität des Saarlandes | 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen |
GB0722779D0 (en) | 2007-11-20 | 2008-01-02 | Sterix Ltd | Compound |
JP5735412B2 (ja) * | 2008-05-05 | 2015-06-17 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung | 11−ベータ−ヒドロキシステロイドデヒドロゲナーゼ−1の阻害剤としてのnipチアゾール誘導体 |
EP2609089A1 (de) | 2010-08-27 | 2013-07-03 | Universität des Saarlandes | Selektive 17-beta-hydroxysteroid-dehydrogenase-typ-1-hemmer |
WO2012119605A1 (en) * | 2011-03-10 | 2012-09-13 | Akar Yahya Ahmed Abdellhafeez Salem | New disperse dye with potent anticancer activity |
JP6461127B2 (ja) | 2013-06-25 | 2019-01-30 | フォレンド ファーマ リミテッド | 17βヒドロキシステロイド脱水素酵素、タイプIの阻害剤としての治療活性エストラトリエンチアゾール誘導体 |
WO2014207310A1 (en) | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase |
JP6456373B2 (ja) | 2013-06-25 | 2019-01-23 | フォレンド ファーマ リミテッド | 17β−ヒドロキシステロイドデヒドロゲナーゼ タイプ1の阻害剤として治療活性のあるエストラトリエンチアゾール誘導体 |
US9884839B2 (en) | 2014-01-03 | 2018-02-06 | Elexopharm Gmbh | Inhibitors of 17Beta-hydroxysteroid dehydrogenases type 1 and type 2 |
WO2016042775A1 (en) * | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
JP6545266B2 (ja) | 2014-12-23 | 2019-07-17 | フォレンド ファーマ リミテッド | 17β‐HSD1抑制剤のプロドラッグ |
WO2016102776A1 (en) | 2014-12-23 | 2016-06-30 | Forendo Pharma Ltd | Prodrugs of 17.beta.-hsd1 -inhibitors |
IL268156B2 (en) | 2017-01-23 | 2025-01-01 | Regeneron Pharma | Variants of 17-beta-hydroxysteroid dehydrogenase and their uses |
RU2019135845A (ru) * | 2017-04-11 | 2021-05-11 | Ридженерон Фармасьютикалз, Инк. | Анализы для скрининга активности модуляторов членов семейства (17-бета)гидроксистероиддегидрогеназ (hsd17b) |
CA3066196C (en) | 2017-06-08 | 2023-08-29 | Forendo Pharma Ltd | 15.beta.-[3-propanamido]-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydro-genases |
WO2019075181A1 (en) | 2017-10-11 | 2019-04-18 | Regeneron Pharmaceuticals, Inc. | INHIBITION OF HSD17B13 IN THE TREATMENT OF HEPATIC DISEASE IN PATIENTS EXPRESSING PNPLA3 I148M VARIATION |
US20210380985A1 (en) | 2018-03-21 | 2021-12-09 | Regeneron Pharmaceuticals, Inc. | 17ß-Hydroxysteroid Dehydrogenase Type 13 (HSD17B13) iRNA Compositions And Methods Of Use Thereof |
US10285998B1 (en) | 2018-04-04 | 2019-05-14 | The Menopause Method, Inc. | Composition and method to aid in hormone replacement therapy |
CN109180702B (zh) * | 2018-10-29 | 2021-11-30 | 四川大学 | 一种噻吩并嘧啶酮化合物及其用途 |
BR112021010598A2 (pt) | 2018-12-05 | 2021-08-24 | Forendo Pharma Ltd | Compostos, método para preparação de um composto e composição farmacêutica |
PH12022550846A1 (en) * | 2019-10-15 | 2023-03-27 | Boehringer Ingelheim Pharma | Thienopyrimidones as trpa1 inhibitors |
EP4323367A1 (de) | 2021-04-14 | 2024-02-21 | Boehringer Ingelheim International GmbH | 3h,4h-thieno[2,3-d pyrimidin-4-on derivate als trpa1 inhibitoren |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4742271B1 (de) * | 1968-06-20 | 1972-10-25 | ||
DE2411273A1 (de) * | 1974-03-06 | 1975-09-18 | Schering Ag | Neue thieno eckige klammer auf 2,3-d eckige klammer zu pyrimidinone und verfahren zu ihrer herstellung |
US5395842A (en) * | 1988-10-31 | 1995-03-07 | Endorecherche Inc. | Anti-estrogenic compounds and compositions |
US5364847A (en) * | 1989-03-10 | 1994-11-15 | Endorecherche | Inhibitors of sex steroid biosynthesis and methods for their production and use |
US5597823A (en) * | 1995-01-27 | 1997-01-28 | Abbott Laboratories | Tricyclic substituted hexahydrobenz [e]isoindole alpha-1 adrenergic antagonists |
JP3783810B2 (ja) | 1997-01-14 | 2006-06-07 | 第一製薬株式会社 | 新規ベンゾフラノン誘導体及びその製造方法 |
JPH10273467A (ja) | 1997-01-29 | 1998-10-13 | Snow Brand Milk Prod Co Ltd | 新規テトラロン又はベンゾピラノン誘導体及びその製造方法 |
JP4166433B2 (ja) | 1997-09-11 | 2008-10-15 | 第一製薬株式会社 | ホルモン依存性疾患治療剤 |
BR9908592A (pt) | 1998-03-11 | 2001-04-24 | Endorech Inc | Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit |
GB9816729D0 (en) | 1998-08-01 | 1998-09-30 | Hoechst Schering Agrevo Gmbh | Substituted cyclohexylaminopyrimidines |
GB9929302D0 (en) | 1999-12-11 | 2000-02-02 | Univ Cardiff | Benzyl tetralins compositions and uses thereof |
WO2002026706A2 (en) | 2000-09-29 | 2002-04-04 | Bayer Pharmaceuticals Corporation | 17-beta-hydroxysteroid dehydrogenase-ii inhibitors |
WO2003017974A1 (en) | 2001-08-31 | 2003-03-06 | Pantarhei Bioscience B.V. | Method of treating benign gynaecological disorders and a pharmaceutical kit for use in such method |
AR036492A1 (es) | 2001-09-06 | 2004-09-15 | Schering Corp | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos inhibidores para la elaboracion de un medicamento para el tratamiento de enfermedades androgeno dependientes |
US6750248B2 (en) | 2001-11-09 | 2004-06-15 | National University Of Singapore | Methods for preparing an estrogenic preparation and isolated estrogenic compounds from a plant and uses thereof |
FI20030393L (fi) | 2003-03-14 | 2004-09-15 | Molekyyliendokrinologian Tutki | Menetelmiä, joilla voidaan ennustaa rintasyövän kehistyskulku ja yhdisteitä, joita voidaan käyttää sen ehkäisemiseksi tai hoitamiseksi |
GB0324792D0 (en) * | 2003-10-23 | 2003-11-26 | Sterix Ltd | Compound |
EP1753736B1 (de) * | 2004-05-24 | 2008-12-17 | Amgen Inc. | Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1 |
-
2004
- 2004-06-07 US US10/861,922 patent/US7754709B2/en not_active Expired - Fee Related
- 2004-06-08 AR ARP040101982A patent/AR044649A1/es not_active Application Discontinuation
- 2004-06-08 TW TW093116412A patent/TW200504078A/zh unknown
- 2004-06-09 DK DK04739738T patent/DK1635840T3/da active
- 2004-06-09 DE DE602004015287T patent/DE602004015287D1/de not_active Expired - Lifetime
- 2004-06-09 PT PT04739738T patent/PT1635840E/pt unknown
- 2004-06-09 CN CNB2004800126362A patent/CN100502876C/zh not_active Expired - Fee Related
- 2004-06-09 ES ES04739738T patent/ES2311156T3/es not_active Expired - Lifetime
- 2004-06-09 AT AT04739738T patent/ATE401893T1/de active
- 2004-06-09 AU AU2004246791A patent/AU2004246791B2/en not_active Ceased
- 2004-06-09 EP EP04739738A patent/EP1635840B1/de not_active Expired - Lifetime
- 2004-06-09 BR BRPI0411319-5A patent/BRPI0411319A/pt not_active IP Right Cessation
- 2004-06-09 PL PL04739738T patent/PL1635840T3/pl unknown
- 2004-06-09 WO PCT/EP2004/006231 patent/WO2004110459A1/en active IP Right Grant
- 2004-06-09 CA CA002527591A patent/CA2527591A1/en not_active Abandoned
- 2004-06-09 JP JP2006515870A patent/JP4612628B2/ja not_active Expired - Fee Related
- 2004-06-12 SA SA04250158A patent/SA04250158B1/ar unknown
-
2006
- 2006-07-07 HK HK06107630.5A patent/HK1087331A1/xx not_active IP Right Cessation
-
2007
- 2007-12-31 US US11/967,989 patent/US20080103131A1/en not_active Abandoned
-
2010
- 2010-06-08 US US12/796,097 patent/US20100249106A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE602004015287D1 (en) | 2008-09-04 |
AR044649A1 (es) | 2005-09-21 |
JP2006527227A (ja) | 2006-11-30 |
US20100249106A1 (en) | 2010-09-30 |
US20080103131A1 (en) | 2008-05-01 |
CN1784234A (zh) | 2006-06-07 |
ES2311156T3 (es) | 2009-02-01 |
DK1635840T3 (da) | 2008-09-01 |
HK1087331A1 (en) | 2006-10-13 |
EP1635840A1 (de) | 2006-03-22 |
PT1635840E (pt) | 2008-09-17 |
AU2004246791A1 (en) | 2004-12-23 |
TW200504078A (en) | 2005-02-01 |
JP4612628B2 (ja) | 2011-01-12 |
CA2527591A1 (en) | 2004-12-23 |
WO2004110459A1 (en) | 2004-12-23 |
BRPI0411319A (pt) | 2006-07-18 |
EP1635840B1 (de) | 2008-07-23 |
US20050032778A1 (en) | 2005-02-10 |
PL1635840T3 (pl) | 2009-01-30 |
US7754709B2 (en) | 2010-07-13 |
AU2004246791B2 (en) | 2010-02-18 |
CN100502876C (zh) | 2009-06-24 |
SA04250158B1 (ar) | 2007-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE401893T1 (de) | Thiophenepyrimidinone als 17-beta-hydroxysteroid dehydrogenase inhibitoren | |
ATE452631T1 (de) | N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer | |
ATE400271T1 (de) | Aryl-pyridinderivate als 11-beta-hsd1-hemmer | |
ATE446090T1 (de) | Thiadiazolidinone als gsk3-inhibitoren | |
ATE525377T1 (de) | Imidazoä1,5-aüpyrazine als inhibitoren von tyrosinkinase | |
ATE437876T1 (de) | Hexahydropyridoisochinoline als dpp-iv- inhibitoren | |
ATE420076T1 (de) | Indozolonderivate als 11b-hsd1-inhibitoren | |
ATE423121T1 (de) | Diphenylimidazopyrimidin- und -imidazolamine als b-sekretase-inhibitoren | |
DE602004015724D1 (de) | Diazepinoindolderivate als kinaseinhibitoren | |
DE602004008136D1 (de) | Härtbare Zusammensetzung | |
DE602004024420D1 (de) | Chinazolinderivate als antitumormittel | |
ATE452635T1 (de) | Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer | |
ATE521607T1 (de) | Piperidinderivate als renin-inhibitoren | |
DE602004008303D1 (de) | Triazolopyrimidinderivate als inhibitoren von glycogensynthasekinase-3 | |
ATE489387T1 (de) | Pyridoä2,1-aü-isochinolinderivate als dpp-iv inhibitoren | |
DE602004012154D1 (de) | Pyridoä2,3-düpyrimidin-2,4-diamine als pde-2-inhibitoren | |
DE602004018837D1 (de) | Ptidase-iv-inhibitoren | |
DE60324208D1 (de) | Biarylsulfonamide als mmp-inhibitoren | |
ATE452132T1 (de) | Benzimidazolthiophenverbindungen als plk- inhibitoren | |
DK1685150T3 (da) | Hidtil ukendte 17beta-hydroxysteroiddehydrogenase type I-inhibitorer | |
ATE462692T1 (de) | 3-amino-1-arylpropyl-indole als monoamin- wiederaufnahmehemmer | |
ATE509011T1 (de) | Pyrimidinderivate als 11beta-hsd1-inhibitoren | |
NO20070299L (no) | Novel heterocyclic compounds | |
DE602004006997D1 (de) | 4-(aminomethyl)-piperidinbenzamide als 5ht4 -antagonisten | |
ATE394372T1 (de) | G-lactamderivate als prostaglandinagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1635840 Country of ref document: EP |